Allergen-specific B-lymphocyte

Allergen-specific B-lymphocytes are a specialized subset of the adaptive immune system responsible for the production of allergen-specific antibodies, most notably Immunoglobulin E (IgE) (Heeringa et al., 2020) [1]. In sensitized individuals, these cells undergo class-switch recombination to IgE upon exposure to specific environmental antigens, such as pollen, dust mites, or food proteins (Galli et al., 2008) [3]. These IgE antibodies then bind to high-affinity receptors on mast cells and basophils, priming them for degranulation upon subsequent allergen exposure, which leads to the clinical symptoms of allergy (Galli et al., 2008) [3]. Therapeutic strategies targeting these cells aim to either deplete the IgE-producing B cell population, induce anergy, or promote class-switching toward protective antibodies like IgG4, which can neutralize allergens before they trigger an allergic response (Shamji & Durham, 2017) [2]. Understanding the dynamics of these cells is crucial for developing precision treatments for allergic diseases like asthma and anaphylaxis (Davies et al., 2013) [4]. Current pharmacological interventions include monoclonal antibodies that block the signaling pathways necessary for B cell activation and class-switching, as well as allergen-specific immunotherapy designed to reprogram the B cell response toward tolerance (Shamji & Durham, 2017) [2]. Notable safety concerns include the risk of systemic allergic reactions during immunotherapy and the potential for broader immunosuppression if non-specific B-cell depletion is employed (Pescovitz, 2006) [5].

Other names

Allergen-specific B cellIgE-producing B cellAllergen-reactive B cellIgE-switched memory B cell

Modulation of B cell differentiation and class-switch recombination to favor IgG4 over IgE; induction of IL-10-producing regulatory B cells (Bregs); blockade of cytokine signaling (IL-4/IL-13) required for IgE synthesis; and direct depletion of B-cell populations.